Skip to main content
LYSOGENE logo

LYSOGENE — Investor Relations & Filings

Ticker · LYS ISIN · FR0013233475 LEI · 969500T64RILK1RD0852 PA Professional, scientific and technical activities
Open in API
Filings indexed 254 across all filing types
Latest filing 2021-01-12 Major Shareholding Noti…
Country FR France
Listing PA LYS

About LYSOGENE

https://www.lysogene.com

Lysogene was a clinical-stage biotechnology company that specialized in the research and development of gene therapies for rare, inherited neurodegenerative diseases affecting the central nervous system (CNS). The company's approach focused on delivering a functional copy of a deficient gene directly to the brain to address the root cause of the targeted disorder. Its pipeline included investigational treatments for lysosomal storage diseases such as Sanfilippo syndrome type A (MPS IIIA) and GM1 gangliosidosis. Following clinical and financial challenges, the company initiated judicial liquidation proceedings in 2023.

Recent filings

Filing Released Lang Actions
Franchissement de seuils
Major Shareholding Notification Classification · 1% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing thresholds (Article L. 233-7 of the Commercial Code)'. It explicitly states that Novo Holding A/S crossed below the 5% threshold of capital and voting rights in LYSOGENE on January 5, 2021. This type of filing, reporting changes in significant share ownership that cross regulatory thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is short and contains the core notification details, confirming it is the filing itself, not an announcement of a filing.
2021-01-12 French
Inside Information / Other news releases
Legal Proceedings Report Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and announces key operational and regulatory milestones: receiving MHRA and Research Ethics Committee approvals to initiate a clinical trial (LYS-GM101) in the UK. It discusses trial enrollment timelines, CEO commentary, orphan drug designations, and ongoing studies. This type of announcement, focusing on significant operational updates, clinical progress, or regulatory milestones outside of mandatory periodic financial reporting (like 10-K or IR), is typically classified as a general Regulatory Announcement or Press Release. Since there is no specific category for 'Press Release' that isn't a financial report, and it is not a formal financial filing (10-K, IR, ER, MRQ), the most appropriate general category is Regulatory Filings (RNS), which serves as a fallback for miscellaneous regulatory/operational announcements not covered elsewhere. It is not an Earnings Release (ER) as it contains no financial results, nor is it a Call Transcript (CT) or Investor Presentation (IP). It is too detailed to be a simple Report Publication Announcement (RPA).
2021-01-11 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 1% confidence The document is titled 'COMMUNIQUE DE PRESSE' (Press Release) and announces that Lysogene has received authorization from the MHRA and Ethics Committee to start a clinical trial in the UK for LYS-GM101. It details the trial's significance, timeline (recruitment in H1 2021), and includes quotes from the CEO. This content is characteristic of an initial announcement regarding a significant operational or clinical development, rather than a comprehensive financial report (10-K, IR) or a formal regulatory filing like a proxy statement or earnings release. Since it is a press release announcing a major operational milestone (clinical trial initiation authorization), it best fits the 'Regulatory Filings' (RNS) category as a general regulatory/corporate announcement, or potentially an 'Earnings Release' (ER) if it were tied to quarterly results, but here it is purely operational news. Given the options, RNS serves as the best general category for significant, non-standardized corporate news releases that aren't explicitly covered elsewhere (like DIV, CAP, or ER). However, since it is a press release announcing a clinical trial milestone, which is crucial operational news, and it is not a formal financial report, RNS is the most appropriate fallback, although it shares characteristics with an ER if the company were smaller or less structured. Given the context of a biotech company announcing trial progress, RNS is the most suitable general regulatory announcement category.
2021-01-11 French
Franchissement de seuils
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" and details a change in shareholding percentage (crossing below 5%) by Caisse des dépôts et consignations (CDC) via Bpifrance Investissement concerning LYSOGENE shares. This type of filing, reporting changes in significant share ownership thresholds, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document is a formal regulatory declaration regarding ownership changes, not a full report or an announcement of a report.
2021-01-06 French
Franchissement de seuils
Director's Dealing Classification · 1% confidence The document is titled "Déclaration de franchissement de seuils (article L. 233-7 du code de commerce)" which translates to 'Declaration of crossing thresholds (Article L. 233-7 of the Commercial Code)'. It details a change in the shareholding percentage (crossing below 5%) by EPIC Bpifrance in LYSOGENE, specifying the number of shares held and the resulting percentage of capital and voting rights. This type of mandatory disclosure regarding significant changes in major share ownership directly corresponds to the definition of Major Shareholding Notification (MRQ). The document length is short (2206 chars), but the content is a specific regulatory filing about share ownership thresholds, not just an announcement of a report's publication.
2021-01-05 French
Inside Information / Other news releases
Earnings Release Classification · 1% confidence The document is explicitly titled "PRESS RELEASE" and reports on positive biomarker data from a clinical trial (AAVance trial with LYS-SAF302 for MPS IIIA). It provides key results, quotes from the CSO, and forward-looking statements, which are characteristic features of an Earnings Release (ER) or a general press release announcing significant operational/clinical updates. Since it focuses on reporting recent results (biomarker data) rather than being a comprehensive annual/interim report (10-K/IR) or a transcript (CT), the most appropriate classification is Earnings Release (ER), as these press releases often accompany or precede formal financial filings to disseminate key performance indicators or operational milestones. It is not a comprehensive financial report (10-K or IR), nor is it a management discussion (MDA) or a presentation (IP). It is a direct announcement of results. FY 2020
2020-12-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.